Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Julia Suchomel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Cyclosporine, Drug Interactions, Healthy Volunteers. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech Inc.
Abstract (Originalsprache)
A study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO ® ) was conducted in 15 healthy adult volunteers. A single 200 mg dose of pralsetinib was administered orally alone and in combination with cyclosporine with a 9‐day washout between treatments. Co‐administration with cyclosporine resulted in a clinically relevant increase in pralsetinib maximum plasma concentration ( C max ) and area under the plasma concentration–time curve extrapolated to infinity (AUC 0–∞ ) with associated geometric mean ratios (GMRs) and 90% confidence intervals (CIs) of 148% (109, 201) and 181% (136, 241), respectively. These findings provide insight into concomitant dosing of pralsetinib with inhibitors of P‐gp given the increases in pralsetinib exposure observed when administered with cyclosporine. Based on these results, co‐administration of pralsetinib with P‐gp inhibitors is not recommended. In the event that co‐administration cannot be avoided, it is recommended that the dose of pralsetinib be reduced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Genentech, Inc., South San Francisco, California, USA.
- Hoffman-La Roche, Basal, Switzerland.
- Syneos Health, Raleigh, North Carolina, USA.
ORCID-Profile: Julia Suchomel, Yang Tang
Förderung
- Genentech Inc
Zitieren
APA
Suchomel, J., Agarwal, P., Anders, D., Hughes, K., Tang, Y., Sane, R., Scalori, A., Sharma, S., & Cheeti, S. (2024). Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations. Clinical and Translational Science. https://doi.org/10.1111/cts.13818
Vancouver
Suchomel J, Agarwal P, Anders D, Hughes K, Tang Y, Sane R, et al. Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations. Clinical and Translational Science. 2024. doi:10.1111/cts.13818
BibTeX
@article{Suchomel2024,
author = {Suchomel, Julia and Agarwal, Priya and Anders, Doreen and Hughes, Kevin and Tang, Yang and Sane, Rucha and Scalori, Astrid and Sharma, Sunil and Cheeti, Sravanthi},
title = {Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13818}
}
EUVIMED